approval · primary record
nogapendekin alfa inbakicept-pmln
FDA · BLA · 2026-10-14
| Agency | FDA |
|---|---|
| Submission type | BLA |
| Latest action | 2026-10-14 |
| Approval events | 1 |
| Brand | ANKTIVA |
| Sponsor | ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU |
| Route | INTRAVESICAL |
Approval history
1 action on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-10-14 | FDA | BLA | ANKTIVA | ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU | INTRAVESICAL |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:32:11.076Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:nogapendekin-alfa-inbakicept-pmln
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Nogapendekin Alfa Inbakicept-Pmln · compound